Researchers are developing a two-part therapy for type 1 diabetes: lab-made insulin-producing cells paired with ...

Your brain begins as a single cell. When all is said and done, it will house an incredibly complex and powerful network of some 170 billion cells. How does it organize itself along the way? Cold ...

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune ...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge ...

Galapagos NV (GLPG) reported FY25 GAAP EPS of €4.87 and €1.11B revenue, driven by one-time accounting from Gilead ...

Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...

Be prepared … or risk annoying the gatekeeper. Imugene’s experience with the FDA shows how regulatory polish can shave years off a drug’s path to approval.

The field of inflammatory response in cardiac surgery is a critical area of research due to the high morbidity and mortality associated with systemic inflammatory response (CS-SIR) evoked by on-pump ...

JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...

Astellas Pharma Inc. and Vir Biotechnology Inc. have signed a global co-development pact to advance VIR-5500, Vir’s PRO-XTEN dual-masked CD3 T-cell engager targeting prostate-specific membrane antigen ...

Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval exp ...

Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization ...